EARDREAM is at the forefront of Alzheimer’s research, leveraging unique biomarkers for early asymptomatic detection and innovating sleep stimulation treatments. Accessing populations carrying definitive Alzheimer's genetic mutations, the startup uses its wearable technology to acquire relevant information and develop predictive and interpretable algorithms that can detect and monitor Alzheimer’s risk in its asymptomatic phase. These insights guide tailored sleep stimulation methods, enhancing deteriorated sleep mechanisms associated with Alzheimer's progression. The multidisciplinary ETH founding team of EARDREAM includes Simon Baur, Stephanie Huwiler, Dr. Caroline Lustenberger, and Prof. Dr. Rafael Polanía.
